Last reviewed 2026-04-23 · How we verify

SCT400 plus CHOP

SCT400 is a small molecule inhibitor of the BCL-2 family, while CHOP is a combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone.

SCT400 is a small molecule inhibitor of the BCL-2 family, while CHOP is a combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma.

At a glance

Mechanism of action

SCT400 works by inhibiting the anti-apoptotic function of BCL-2, allowing for programmed cell death in cancer cells. CHOP is a traditional chemotherapy regimen that targets rapidly dividing cancer cells.

Approved indications

• Relapsed or refractory diffuse large B-cell lymphoma
• Relapsed or refractory follicular lymphoma

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia
• Fatigue
• Nausea

Key clinical trials

• A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.